{"filing":{"accession_number":"0001193125-26-381098","cik":"0001671584","ticker":"APVO","company_name":"Aptevo Therapeutics Inc.","form":"8-K","filing_date":"2026-09-03","report_date":"2026-09-03","primary_document":"apvo-20260903.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526381098/apvo-20260903.htm"},"events":[{"id":31490,"run_id":28897,"accession_number":"0001193125-26-381098","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Aptevo announced positive interim clinical trial results for mipletamig in TP53-mutated AML patients, reporting a 93% clinical benefit rate and 79% CR/CRi rate that compares favorably to published benchmarks. This is a material operational/clinical milestone for a clinical-stage biotech company, as it represents significant progress in a lead program and addresses an unmet medical need in a difficult-to-treat patient population. While not a formal earnings release or regulatory approval, the clinical data disclosure is material to investors' assessment of the company's pipeline value and development trajectory.","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34394,"accession_number":"0001193125-26-381098","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aptevo announced positive interim clinical trial results for mipletamig in TP53-mutated AML patients, reporting a 93% clinical benefit rate and 79% CR/CRi rate that compares favorably to published benchmarks. This is a material operational/clinical milestone for a clinical-stage biotech company, as it represents significant progress in a lead program and addresses an unmet medical need in a difficult-to-treat patient population. While not a formal earnings release or regulatory approval, the clinical data disclosure is material to investors' assessment of the company's pipeline value and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:16:42.584136+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34394,"accession_number":"0001193125-26-381098","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aptevo announced positive interim clinical trial results for mipletamig in TP53-mutated AML patients, reporting a 93% clinical benefit rate and 79% CR/CRi rate that compares favorably to published benchmarks. This is a material operational/clinical milestone for a clinical-stage biotech company, as it represents significant progress in a lead program and addresses an unmet medical need in a difficult-to-treat patient population. While not a formal earnings release or regulatory approval, the clinical data disclosure is material to investors' assessment of the company's pipeline value and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:16:42.584136+00:00","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-09-03"}]}